Things look even worse for Mylan CEO Heather Bresch as she heads to Capitol Hill

Mylan N.V. Chief Executive Heather Bresch will have even more to answer for as she heads to Capitol Hill Wednesday to testify before the House Oversight Committee, with her testimony coming on the heels of new critical reports about the company’s price increases on the EpiPen allergic reaction treatment.

Government spending on Medicare Part D beneficiaries for the EpiPen increased more than 1,000% between 2007 and 2014, driven mainly by EpiPen price increases, according to a new analysis by the Kaiser Family Foundation.

In addition, Bresch’s mother, who led a national education group representing state boards of education for several years, was instrumental in advocating for more access to allergic reaction treatments in schools — where Mylan’s MYL, +0.61% EpiPens clearly benefited, according to a Tuesday USA Today report.

>>> Original Source <<<